Company news

Dianthus Therapeutics, Inc. news in 2025

Dianthus Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

December 22, 2025

Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference

November 23, 2025

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

November 4, 2025

Dianthus Therapeutics to Participate in Four Investor Conferences During November

November 3, 2025

Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting

October 28, 2025

Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases

October 15, 2025

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting

October 1, 2025

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

September 10, 2025

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering

September 8, 2025

Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering

September 7, 2025

Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile

September 7, 2025

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

September 6, 2025

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

August 6, 2025

Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference

May 28, 2025

Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors

May 21, 2025

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

May 11, 2025

Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September

May 4, 2025

Dianthus Therapeutics to Participate in Two Upcoming Investor Events

April 28, 2025

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results

March 10, 2025

Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors

March 4, 2025

Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences

February 25, 2025

Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences

January 29, 2025

Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

January 7, 2025

Decks in 2025